• Chlorambucil: Interpreting In Vitro Evidence

  2026-10-10

  A source-grounded overview of how to interpret chlorambucil research, with emphasis on DNA damage, viability metrics, evidence quality, model dependence, and the limits of translating in vitro findings to chronic lymphocytic leukemia treatment.

• Arachidonic Acid and Faster Humoral Immunity

  2026-10-09

  A 2025 EMBO Molecular Medicine study reports that dietary arachidonic acid enhanced rabies vaccine-induced antibody responses in mice and accelerated protective neutralizing antibody development in human volunteers. The work links arachidonic acid metabolism in lymph nodes to PGI2–cAMP–PKA signaling, CD86 expression, and B-cell activation, while leaving important questions about clinical applicability and whether related fatty acids such as EPA produce comparable effects.

• Sex Differences in Angiotensin II Hypertension

  2026-10-09

  Xue, Pamidimukkala, and Hay showed that chronic angiotensin II exposure produced a substantially larger blood-pressure increase in conscious male mice than in females. By combining telemetry with gonadectomy, baroreflex assessment, and autonomic blockade, the study linked this divergence to sex-dependent hormonal and sympathetic mechanisms while defining important limits for interpretation.

• Methylprednisolone Sodium Succinate: Evidence Map

  2026-10-08

  Methylprednisolone Sodium Succinate is a synthetic corticosteroid with research relevance across inflammation, immune-cell biology, tumor apoptosis, and acute injury models. This evidence map separates established mechanisms, supplier-reported findings, translational signals, and the interpretive limits of cross-study comparisons.

• Dual HER2–VEGFR-2 Targeting in Breast Cancer

  2026-10-08

  A 2026 study examined Lapatinib and Telatinib as a combined strategy for suppressing invasion-related phenotypes and angiogenesis-associated behavior in a triple-negative breast cancer model. Its findings support further HER2/VEGFR-2 pathway investigation, while the receptor-negative model requires careful interpretation because reduced phenotypes do not by themselves prove HER2 target engagement.

• METTL16–SENP3–LTF Axis in HCC Ferroptosis

  2026-10-07

  Wang et al. identify a METTL16–SENP3–LTF regulatory axis that protects hepatocellular carcinoma cells from ferroptosis by altering iron availability. The study connects m6A-dependent RNA regulation with de-SUMOylation, LTF stability, tumor progression, and clinical prognosis across cellular, organoid, animal, and human-sample evidence.

• Protein Corona Formation and Nanoparticle Function

  2026-10-07

  Elizabeth Voke’s 2025 UC Berkeley dissertation examines how protein corona formation changes nanoparticle behavior across plant and mammalian contexts. Its most consequential finding is that greater lipid nanoparticle uptake does not necessarily produce greater mRNA expression, emphasizing the importance of tracking intracellular trafficking rather than relying on uptake alone.

• TMEM16F, Ferroptosis, and Tumor Immune Rejection

  2026-10-06

  A 2025 Science Advances study identifies TMEM16F-mediated plasma-membrane lipid scrambling as a late-stage suppressor of ferroptotic membrane failure. The findings connect membrane biophysics with tumor immunology, showing that blocking this adaptive response can intensify ferroptosis, expose danger signals, and improve responses to PD-1 blockade in tumor models.

• DMG-PEG2000-N3: From Clickable Lipid to Translation

  2026-10-06

  A source-grounded perspective on how DMG-PEG2000-N3 may support modular bioconjugation and lipid-based delivery research, while separating supplier-described chemistry from evidence generated in nucleic acid lipid nanoparticle studies.

• Superoxide Dismutase Activity Assay Kit Overview

  2026-10-05

  APExBIO’s K2035 is a research-use SOD activity kit based on a vendor-described colorimetric assay concept. No matched paper evidence was provided, so independent performance and broader applicability remain unverified.

• Superoxide Dismutase Activity Assay Kit Overview

  2026-10-05

  APExBIO’s SKU K2035 is described as a colorimetric Superoxide Dismutase Activity Assay Kit for measuring SOD activity in biological fluids. No matched paper evidence was supplied, so independent performance, matrix compatibility, and biological interpretation are not established here.

• TG003 Cdc2-like Kinase Inhibitor: Evidence

  2026-10-04

  TG003 is a Cdc2-like kinase inhibitor used to study serine/arginine-rich protein phosphorylation and alternative splicing modulation. Vendor-reported biochemical data support strong activity against Clk1 and Clk4, while a 2024 ovarian cancer study supports CLK2 as a platinum-resistance mechanism but does not establish TG003 as a treatment for platinum-resistant disease.

• Dual SMAD/Wnt Inhibition for iPSC-RGC Differentiation

  2026-10-03

  Chavali and colleagues reported a chemically defined, non-genetic strategy that directs induced pluripotent stem cells toward retinal ganglion cells through coordinated SMAD and canonical Wnt pathway inhibition. The approach produced more than 80% RGC purity before enrichment and nearly 95% Thy-1-positive cells after selection, supporting more reproducible in vitro models of glaucoma-related neurobiology.

• RGFP966 for HO-1 Activity Studies

  2026-10-02

  RGFP966 can add a causal HDAC3-directed perturbation arm to live-cell HO-1 activity measurements, helping distinguish altered enzyme function from changes in abundance. Pairing it with the aminocoumarin probe workflow enables spatial, temporal, and serum-oriented studies that complement conventional HMOX1 transcript or protein assays.

• Pheromone-Driven Neurodegeneration in C. elegans

  2026-10-01

  Peng et al. show that early-life perception of the pheromones ascr#3 and ascr#10 can remodel neural development and accelerate adult neurodegeneration in C. elegans through coordinated ASK, ASI, and AIA signaling. The study provides a mechanistic framework linking environmental chemical cues to insulin-like signaling and reduced neuronal autophagy, while also illustrating why genetic and molecular validation must remain distinct from routine PCR workflow support.

8530 records 1/569 page Next 12345 下5页 Last page